Edwards Lifesciences Corporation has reported that its Sapien transcatheter heart valve substantially improved the quality of life in patients with inoperable aortic stenosis in a clinical trial.

The randomised and controlled trial of involved 358 patients, who were assessed upon enrolment and at follow-up intervals of one month, six months and 12 months.

Information was collected using scientifically validated surveys, including the Kansas City cardiomyopathy questionnaire (KCCQ), the SF-12 health status survey and the EQ-5D.

On a scale of 0 to 100, where 20-point improvement is considered to be significant, patients treated with Edwards transcatheter valve reported a 25-point improvement in quality of life scores compared to the control group, based on KCCQ.

Positive results were also seen for two other surveys.